Abstract
The molecular basis for DNA haplotype-dependent debrisoquine 4-hydroxylase (CYP2D6) expression was explored by sequencing all of the nine exons of the CYP2D6 gene. Two distinct exon sequence frameworks of the CYP2D6 gene were found, each associated with specific BamHI-defined DNA haplotypes of the CYP2D cluster. They corresponded to Arg296/Cys296 and Ser486/Thr486 amino acid polymorphisms in the CYP2D6 enzyme, and occurred in almost equal frequency among the Caucasians examined. These two major allozymes with amino acid differences in the presumed substrate recognition region and in the vicinity of the heme binding site could be the source of the observed DNA haplotype-dependent variation in phenotypic expression.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Armstrong M, Daly AK, Cholerton S, Bateman DN, Idle JR (1992) Mutant debrisoquine genes in Parkinson's disease. Lancet 339:1017–1018
Armstrong M, Idle JR, Daly AK (1993) A polymorphic CfoI site in exon 6 of the human cytochrome P450 CYP2D6 gene detected by polymerase chain reaction. Hum Genet 91:616–617
Ayesh R, Idle JR, Ritchie J, Crothers M, Hetzel M (1984) Metabolic oxidation phenotypes as markers for susceptibility to lung cancer. Nature 312:169–170
Broly F, Gaedigk A, Heim A, Eichelbaum M, Morike K, Meyer UA (1991) Debrisoquine/sparteine hydroxylation genotypes and phenotypes: analysis of common mutations and alleles of CYP2D6 in a European population. DNA Cell Biol 10:545–558
Brosen K (1990) Recent developments in hepatic drug oxidation. Implications for clinical pharmacokinetics. Clin Phannacokinet 18:220–239
Caporaso NE, Shields PG, Landi MT, Shaw GL, Tucker MA, Hoovez R, Sugimura H, Weston A, Harris CC (1992) The debrisoquine metabolic phenotype and DNA-based assays: implications of misclassification for the association of lung cancer and the debrisoquine metabolic phenotype. Environ Health Perspect 98:101–105
Daly AK, Armstrong M, Monkman SC, Idle ME, Idle JR (1991) Genetic and metabolic criteria for the assignment of debrisoquine 4-hydroxylation (cytochrome P4502D6) phenotypes. Pharmacogenetics 1:33–41
Eichelbaum M, Spannbrucker N, Steincke B, Dengler HJ (1979) Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol 16:183–187
Gaedigk A, Blum M, Gaedigk R, Eichelbaum M, Meyer UA (1991) Deletion of the entire cytochrome P450IID6 gene as a cause of impaired drug metabolism in poor metabolizers of debrisoquine/sparteine polymorphism. Am J Hum Genet 48:943–950
Gonzalez FJ, Skoda RC, Kimura S, Umeno M, Zanger UM, Nebert DW, Gelboin HV, Hardwick JP, Meyer UA (1988a) Characterization of the common genetic defect in humans deficient debrisoquin metabolism. Nature 331:442–446
Gonzalez FJ, Vilbois F, Hardwick JP, McBride OW, Nebert DW, Gelboin HV, Meyer UA (1988b) Human debrisoquine 4-hydroxylase (P450IID1): cDNA and deduced amino acid sequence and assignment of the CYPIID locus to chromosome 22. Genomics 2:174–179
Gotoh (1992) Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analysis of amino acid and coding nucleotide sequences. J Biol Chem 267:83–90
Gough AC, Miles JS, Spurr NK, Moss JE, Gaedigk A, Eichelbaum M, Wolf CR (1990) Identification of the primary gene defect at the cytochrome P450 CYP2D locus. Nature 347:773–776
Gough AC, Smith CAD, Howell SM, Wolf CR, Bryant SP, Spurr NK (1992) Localization of the CYP2D gene locus to human chromosome 22q13. l by polymerase chain reaction, in situ hybridization, and linkage analysis. Genomics 15:430–432
Kagimoto M, Heim M, Kagimoto K, Zeugin T, Meyer UA (1990) Multiple mutations of the human cytochrome P450IID6 gene in poor metabolizers of debrisoquine. Biol Chem 265:17209–17214
Kimura S, Umeno M, Skoda RC, Meyer UA, Gonzalez FJ (1989) The human debrisoquine 4-hydroxylase locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene and a pseudogene. Am J Hum Genet 45:889–904
Maghoub A, Idle JR, Dring LG, Lancester R, Smith RL (1977) Polymorphic hydroxylation of the debrisoquine in man. Lancet 11:584–586
Mura C, Panserat S, Vincent-Viry M, Galteau MM, Jacqz-Aigrain E, Krishnamoorthy R (1993) DNA haplotype dependency of debrisoquine 4-hydroxylase (CYP2D6) expression among extensive metabolizers. Hum Genet 92:367–372
Poulos TL, Finzel BC, Gunsalus IC, Wagner GC, Kraut J (1985) The 2,6 A crystal structure of Pseudomonas putida cytochrome P-450. J Biol Chem 30:16122–16130
Poulos TL, Finzel BC, Howard AJ (1986) Crystal structure of substrate-free Pseudomonas putida cytochrome P450. Biochemistry 25:5314–5322
Poulos TL, Finzel BC, Howard AJ (1987) High-resolution crystal structure of cytochrome P450cam. J Mol Biol 195:687–700
Sanger F, Nicklen S, Coulson AR (1977) DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci USA 74:5463–5467
Shimizu T, Hirano K, Takahashi M, Hatano M, Fujii-Kuriyama Y (1988) Site-directed mutageneses of rat liver cytochrome P-450d: Axial ligand and heme incorporation. Biochemistry 27:4138–4141
Smith CAD, Moss JE, Gough AC, Spurr NK, Wolf CR (1992a) Molecular genetic analysis of the cytochrome P450-debrisoquine hydroxylase locus and association with cancer susceptibility. Environ Health Perspect 98:107–112
Smith CAD, Gough AC, Leigh PN, Summers BA, Harding AE, Marangore DM, Sturman SG, Shapira A, Williams AC, Spurr NK, Wolf CR (1992b) Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease. Lancet 339:1375–1377
Tsuneoka Y, Matsuo Y, Twahashi K, Takeuchi H, Ichikawa Y (1993) A novel cytochrome P450IID6 mutant gene associated with Parkinson's disease. J Biochem 114:263–266
Tyndale RF, Inaba T, Kalow W (1989) Evidence in humans for variant allozymes of the nondeficient sparteine/debrisoquine onooxygenase (P450IID1) in vitro. Drug Metab Dispos 17:334–341
Vetticaden SJ, Cabana BE, Prasard VK, Purich ED, Lonkman JHJ, Zeeuw R, Ball LA, Leeson LJ, Braun RL (1989) Phenotypic differences in dextromethorphan metabolism. Pharmacol Res 6:13–19
Wang SL, Huang JD, Lai MD, Liu BH, Lai ML (1993) Molecular basis of genetic variation in debrisoquine hydroxylation in Chinese subjects: polymorphism in RFLP and DNA sequence in CYP2D6. Clin Pharmacol Ther 53:410–418
Wolf CR, Smith CAD, Gough AC, Moss JE, Vallis KA, Howard G, Garey FJ, Mills K, McNee WM, Carmichael J, Spurr NK (1992) Relationship between the debrisoquine hydroxylase polymorphism and cancer susceptibility. Carcinogenesis 13:1035–1038
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Panserat, S., Mura, C., Gérard, N. et al. DNA haplotype-dependent differences in the amino acid sequence of debrisoquine 4-hydroxylase (CYP2D6): evidence for two major allozymes in extensive metabolisers. Hum Genet 94, 401–406 (1994). https://doi.org/10.1007/BF00201601
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF00201601